题名 | Clinical Value Of Apatinib As A Salvage Treatment In Patients With Chemo-Refractory Advanced Cervical Cancer |
作者 | |
发表日期 | 2019 |
发表期刊 | ONCOTARGETS AND THERAPY 影响因子和分区 |
语种 | 英语 |
原始文献类型 | Article |
关键词 | cervix carcinoma YN968D1 antiangiogenesis drug efficacy safety |
其他关键词 | ENDOTHELIAL GROWTH-FACTOR ; PHASE-II TRIAL ; HEPATOCELLULAR-CARCINOMA ; GASTRIC-CANCER ; SOLID TUMORS ; CHEMOTHERAPY ; BEVACIZUMAB ; EFFICACY ; YN968D1 ; CARBOPLATIN |
摘要 | Purpose: Apatinib is effective and safe for several advanced or metastatic cancers, but its therapeutic value in cervical cancer is still unknown. The aim of the study was to assess the therapeutic value of apatinib in patients with chemo-refractory advanced cervical cancer. Patients and methods: This was a retrospective study of patients with advanced cervical cancer treated with apatinib between April 2015 and December 2018 at the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. Patients had to have failed at least 2 lines of chemotherapy prior to receiving apatinib. The clinical tumor response was evaluated after 4 weeks of apatinib treatment, and then every 8 weeks (two cycles). Progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse events were evaluated. Results: Twenty-five patients were included in this study. The median PFS was 5.8 months (95% CI, 4.65-6.95), and the median OS was 12.2 months (95% CI, 8.99-15.41). ORR was 48% and DCR was 96%. Complete response was not observed. The most common adverse events in this study (all grades) were hand-foot syndrome (48%), hypertension (20%), and mouth mucositis (20%). Conclusion: Apatinib monotherapy showed good therapeutic value with tolerable adverse events for patients with chemo-refractory advanced cervical cancer. |
资助项目 | Wenzhou Municipal Science and Technology Bureau [2018H0004] |
出版者 | DOVE MEDICAL PRESS LTD |
出版地 | ALBANY |
ISSN | 1178-6930 |
卷号 | 12页码:9707-9713 |
DOI | 10.2147/OTT.S230406 |
页数 | 7 |
WOS类目 | Biotechnology & Applied Microbiology ; Oncology |
WOS研究方向 | Biotechnology & Applied Microbiology ; Oncology |
WOS记录号 | WOS:000496427000001 |
收录类别 | SCIE ; PUBMED ; SCOPUS |
URL | 查看原文 |
PubMed ID | 32009803 |
PMC记录号 | PMC6859957 |
SCOPUSEID | 2-s2.0-85075335136 |
通讯作者地址 | [Xie, Congying]Department of Radiotherapy and Chemotherapy,The First Affiliated Hospital of Wenzhou Medical University,No. 2 Fuxue Street,Wenzhou,325000,China |
Scopus学科分类 | Oncology;Pharmacology (medical) |
引用统计 | |
文献类型 | 期刊论文 |
条目标识符 | https://kms.wmu.edu.cn/handle/3ETUA0LF/14160 |
专题 | 附属第一医院 第二临床医学院、附属第二医院、育英儿童医院 第二临床医学院、附属第二医院、育英儿童医院_影像医学与核医学_超声科 |
通讯作者 | Xie, Congying |
作者单位 | 1.Department of Radiotherapy and Chemotherapy,The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China; 2.Derpartment of Ultrasonography,The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China; 3.Department of Thyroid and Breast Surgery,The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,China |
第一作者单位 | 附属第一医院; 第一临床医学院(信息与工程学院)、附属第一医院 |
通讯作者单位 | 附属第一医院; 第一临床医学院(信息与工程学院)、附属第一医院 |
第一作者的第一单位 | 附属第一医院 |
推荐引用方式 GB/T 7714 | Su, Meng,Gao, Ya,Ye, Xuxue,et al. Clinical Value Of Apatinib As A Salvage Treatment In Patients With Chemo-Refractory Advanced Cervical Cancer[J]. ONCOTARGETS AND THERAPY,2019,12:9707-9713. |
APA | Su, Meng., Gao, Ya., Ye, Xuxue., Zhou, Qingyu., Zhao, Lihao., ... & Xie, Congying. (2019). Clinical Value Of Apatinib As A Salvage Treatment In Patients With Chemo-Refractory Advanced Cervical Cancer. ONCOTARGETS AND THERAPY, 12, 9707-9713. |
MLA | Su, Meng,et al."Clinical Value Of Apatinib As A Salvage Treatment In Patients With Chemo-Refractory Advanced Cervical Cancer".ONCOTARGETS AND THERAPY 12(2019):9707-9713. |
条目包含的文件 | 条目无相关文件。 |
个性服务 |
查看访问统计 |
谷歌学术 |
谷歌学术中相似的文章 |
[Su, Meng]的文章 |
[Gao, Ya]的文章 |
[Ye, Xuxue]的文章 |
百度学术 |
百度学术中相似的文章 |
[Su, Meng]的文章 |
[Gao, Ya]的文章 |
[Ye, Xuxue]的文章 |
必应学术 |
必应学术中相似的文章 |
[Su, Meng]的文章 |
[Gao, Ya]的文章 |
[Ye, Xuxue]的文章 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论